Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sarclisa
Pharma
After FDA delay, Sanofi scores subcutaneous OBI nod for Sarclisa
Sanofi has gained FDA approval of its subcutaneous version of Sarclisa, which can be delivered manually or by way of an on-body injector.
Kevin Dunleavy
Jul 10, 2026 9:18am
Sanofi's Sarclisa SC, delivered by on-body injector, matches IV
Jun 3, 2025 8:15am
Sanofi's subQ version of Sarclisa measures up to its IV version
Jan 9, 2025 11:14am
J&J counters Sanofi's Sarclisa nod with Darzalex data drop
Sep 27, 2024 3:59pm
Sanofi moves on J&J's Darzalex in first-line myeloma with FDA nod
Sep 20, 2024 4:06pm
ASCO: Sanofi's Sarclisa looks to step out of J&J's myeloma shadow
Jun 3, 2024 4:00pm
